Decitabine combined with RDHAP regimen in relapsed/refractory diffuse large B cell lymphoma

Area of Science:

• Hematology
• Oncology
• Clinical Trials

Background:

• Relapsed/refractory diffuse large B-cell lymphoma (R/R-DLBCL) presents a significant unmet medical need.
• Effective salvage therapies are crucial for improving outcomes in R/R-DLBCL patients.

Purpose of the Study:

• To evaluate the efficacy and safety of decitabine in combination with rituximab, cisplatin, cytarabine, and dexamethasone (decitabine-RDHAP) for R/R-DLBCL.
• To compare the decitabine-RDHAP regimen against the standard RDHAP regimen in R/R-DLBCL patients.

Main Methods:

• A clinical trial involving 56 patients with R/R-DLBCL, divided into decitabine-RDHAP (n=35) and RDHAP (n=21) groups.
• Primary endpoints included overall response rate (ORR) and duration of remission (DOR).
• Secondary endpoints assessed toxicity, progression-free survival (PFS), and overall survival (OS).

Main Results:

• The ORR was similar between groups (40% for decitabine-RDHAP vs. 33% for RDHAP).
• The decitabine-RDHAP regimen demonstrated a significantly longer duration of remission (p=0.044).
• Median PFS and OS were numerically higher in the decitabine-RDHAP group, with no significant differences in adverse events between groups.

Conclusions:

• The decitabine-RDHAP regimen is an effective and well-tolerated treatment option for R/R-DLBCL.
• This combination therapy represents a promising salvage regimen for patients with R/R-DLBCL.
• Further investigation into decitabine-RDHAP for R/R-DLBCL is warranted.